Pfizer plans to launch REMICADE biosimilar in US in November
Pfizer said it will begin shipping INFLECTRA (infliximab-dyyb)for injection, a biosimilar of REMICADE (infliximab) to wholesalers in the US in late November 2016.
INFLECTRA will be the first biosimilar monoclonal antibody (mAb) and only the second biosimilar to be available in the U.S.
